WO2000043535A2 - Composition and device for detecting leukocytes in urine - Google Patents

Composition and device for detecting leukocytes in urine Download PDF

Info

Publication number
WO2000043535A2
WO2000043535A2 PCT/US2000/001333 US0001333W WO0043535A2 WO 2000043535 A2 WO2000043535 A2 WO 2000043535A2 US 0001333 W US0001333 W US 0001333W WO 0043535 A2 WO0043535 A2 WO 0043535A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
compound
salt
unsubstituted
alkenyl
Prior art date
Application number
PCT/US2000/001333
Other languages
French (fr)
Other versions
WO2000043535A3 (en
Inventor
Nam-Won Huh
Original Assignee
Hypoguard America Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/365,322 external-priority patent/US6348324B1/en
Priority claimed from US09/365,592 external-priority patent/US6528652B1/en
Application filed by Hypoguard America Limited filed Critical Hypoguard America Limited
Priority to EP00904434A priority Critical patent/EP1163360A2/en
Priority to AU26195/00A priority patent/AU2619500A/en
Priority to JP2000594943A priority patent/JP2002535342A/en
Priority to CA002359689A priority patent/CA2359689A1/en
Publication of WO2000043535A2 publication Critical patent/WO2000043535A2/en
Publication of WO2000043535A3 publication Critical patent/WO2000043535A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Definitions

  • This invention relates generally to compounds, compositions, devices, and methods useful for detecting the presence of leukocytes through the activity of leukocyte esterases and proteinases in urine.
  • a basic method to measure the number of leukocytes in urine by microscope has been widely available for some time.
  • the disadvantages of this method include the investment of time and money in obtaining and installing the appropriate instrumentation. Further, false negatives can be obtained when samples are allowed to sit too long before analysis.
  • indicator assays that are suitable for detecting leukocytes more easily, conveniently, and accurately.
  • Typical indicator assays use a specific chemical substance (e.g., a substrate) that is degraded by one or more enzymes present in leukocytes to create a product suitable for effectuating a visible color change.
  • leukocyte assay involves the use of peroxidase that is contained in a granular leukocyte.
  • This assay includes a filter paper stained with hydrogen peroxide and ⁇ -tolidine, which shows a colored oxidative product when contacted with leukocytes.
  • this assay is less than desirable because peroxidase can be dangerous and reductive materials in urine may make actual application impractical.
  • Other methods designed to confirm the presence of esterase and proteinase in leukocytes have also been developed. For example, one method uses a colorless or pale-colored ester compound as a substrate that is degraded by esterase into a colorless acid moiety and an alcoholic moiety.
  • This assay allows for the determination of leukocyte concentration by the naked eye. Yet the use of this assay is less than desirable because the diazonium salt may react with urobilinogen or bilirubin contained in urine. As a result, concentrations of leukocytes greater than 500 cells/ ⁇ l are often necessary to avoid a false-negative reading.
  • U.K. Patent No. 1,128,371 discloses other possible substrates, i.e., colorless indoxyl or thioindoxylesters. These substrates are degraded into indoxyl or thioindoxyl by esterase. Colored indigo or thioindigo may then be produced by reaction with oxygen in the air or by an oxidizer. Yet the use of an assay with these substrates is less than desirable because this is not sensitive and fails to detect leukocytes at a concentration less than 10,000 cells/ ⁇ l.
  • U.S. Patent No. 4,278,763 suggests indoxyl-type substrates by disclosing a method of using indoxyl or thioindoxylamino acid ester as a substrate.
  • U.S. Patent No. 4,704,460 discloses use of an amino acid ester of a pyrrole derivative as a substrate. When this derivative is degraded in the presence of diazonium salt, a change in sample color to deep violet results. Moreover, the addition of a nucleophilic alcohol, such as decanol, greatly facilitates reaction rate, and in turn, allows detection of leukocyte concentrations as low as 10 cells/ ⁇ l within 90 seconds. Yet this assay is less than desirable because the syntheses of these two substrates is very difficult.
  • the above-described assays are characterized by numerous disadvantages. Some disadvantages include the detection of false negatives, the interference of urobilinogen or bilirubin, the lack of sensitivity, and the requirement of less-than- desirable substrates. Thus, it would be desirable to identify new compounds and methods of using the compounds to detect the presence of leukocytes in urine.
  • the invention is directed to thiazole esters suitable for detecting leukocytes in urine, compositions containing thiazole esters, diagnostic devices suitable for detecting leukocytes in urine, and methods of using the thiazole esters or compositions thereof for detecting leukocytes in urine.
  • this invention is directed to novel thiazole esters.
  • One thiazole ester according to this invention is of the formula:
  • A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine;
  • Ri is unsubstituted or substituted heteroaryl; alkenyl substituted with unsubstituted or substituted aryl; or alkenyl substituted with unsubstituted or substituted heteroaryl.
  • Ri may be thienyl, pyridyl, furyl, styryl, pyrrolyl, or indolyl.
  • Another thiazole ester according to this invention is of the formula:
  • A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine;
  • R 2 is unsubstituted or substituted fused hydrocarbyl rings in which at least one ring is aromatic.
  • R 2 may be naphthyl or anthryl.
  • Another thiazole ester according to this invention is of the formula:
  • A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine; and R 3 and Rt are each independently hydrogen, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxy, amino, unsubstituted or substituted acyl, halo, nitro, cyano. -SO H, or hydroxy, with the proviso that R 3 and R 4 are not both hydrogen.
  • compositions that include a thiazole ester of formula I, II, or III.
  • Compositions of the invention may also include a diazonium salt such as 2-methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt.
  • diagnostic devices that include a compound or composition of the invention. Such diagnostic devices include a substrate having a thiazole ester of formula I, II, or III deposited thereon.
  • the compounds, compositions, and diagnostic devices of the invention are also suitable for use in methods for detecting leukocytes in urine.
  • Methods for detecting leukocytes in urine include contacting a thiazole ester of the invention and a diazonium salt with a urine sample.
  • the compounds and compositions suitable for use in devices and methods of the invention are typically pharmaceutically acceptable.
  • compositions, diagnostic devices, and methods of the invention can be free of accelerating salt.
  • the invention is directed to detecting leukocytes in urine.
  • the presence of leukocytes is typically detected by detecting the presence of enzymes known in the art as leukocyte esterases and leukocyte proteinases that are present with leukocytes.
  • Compounds of the invention include thiazole esters that contain an ester functionality, which is hydrolyzed upon exposure to leukocytes in urine. The hydrolysis of the ester of a thiazole ester of the invention provides a useful diagnostic technique because thiazolyl can react with a diazonium salt to produce an azo dye.
  • the compounds according to this invention are thiazole esters that are suitable for use in compositions, diagnostic devices, and methods that can be used to detect leukocytes in urine.
  • One thiazole ester suitable for use in compositions and methods of the invention is of the formula: or a salt or solvated salt thereof, in which A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-alanine-alanine, and the like), being blocked at the amino terminus by protecting groups known in the art, such as, for example, benzyloxycarbonyl, t-butoxycarbonyl, and -toluenesulfonyl; and Ri is unsubstituted or substituted heteroaryl; alkenyl substituted with unsubstituted or substituted aryl; or alkenyl substituted with unsubstituted or substituted heteroaryl.
  • A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N
  • heteroaryl includes heterocyclic aromatic derivatives having at least one heteroatom, such as, for example, nitrogen, oxygen, phosphorus, or sulfur, and includes, for example, furyl, pyrrolyl, thienyl, oxazolyl, pyridyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, and the like.
  • heteroaryl also includes fused rings in which at least one ring is aromatic, such as, for example, indolyl, purinyl, benzofuryl, benzothienyl, quinolyl, 4,5,6,7-tetrahydro-lH-indolyl, and the like.
  • fused rings that have a hydrocarbyl ring fused to a heterocyclic ring, such as, for example, benzothienyl and indolyl
  • the fused rings may be bonded to thiazolyl through either the hydrocarbyl ring or the heterocyclic ring.
  • heteroaryl includes a 5-membered ring.
  • heteroaryl includes a 6-membered ring.
  • Such heteroaryl groups may be unsubstituted or substituted on the ring by, for example, aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO 3 ⁇ , or hydroxy, in which such substituents may further be substituted by aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO 3 H, or hydroxy.
  • heteroaryl is substituted with alkyl, such as methyl, ethyl, propyl, or butyl.
  • heteroaryl is substituted with alkoxy, such as methoxy, ethoxy, propoxy, or butoxy.
  • heteroaryl is substituted with aryl or heteroaryl.
  • aryl includes aromatic hydrocarbyl, such as, for example, phenyl, including fused aromatic rings, such as, for example, naphthyl, anthryl, and the like.
  • alkyl includes a straight or branched saturated aliphatic hydrocarbon chain having from 1 to 4 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, t-butyl (1,1-dimethylethyl), and the like.
  • alkenyl includes an unsaturated aliphatic hydrocarbon chain having from 2 to 4 carbon atoms, such as, for example, ethenyl, 1-propenyl, 2- propenyl, 1-butenyl, 2-methyl- 1-propenyl, and the like.
  • the above alkyl or alkenyl groups may optionally be interrupted in the chain by a heteroatom, such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.
  • a heteroatom such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.
  • alkoxy includes alkyl as defined above joined to an oxygen atom having from 1 to 4 carbon atoms in a straight or branched chain, such as, for example, methoxy, ethoxy, propoxy, isopropoxy (1-methylethoxy), butoxy, t- butoxy (1,1-dimethylethoxy), and the like.
  • amino includes a substituent of the formula -N(R 5 ) 2 in which each R 5 is independently hydrogen or alkyl.
  • alkyl is as defined above.
  • alkenyl substituted with unsubstituted or unsubstituted aryl or “alkenyl substituted with unsubstituted or substituted heteroaryl” includes alkenyl as defined above, and such groups are substituted with unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl, respectively.
  • aryl and heteroaryl are as defined above. Examples of suitable substituted alkenyls include styryl, cinnamyl, furylethenyl, pyridylethenyl, andthienylpropenyl.
  • alkenyl substituted with unsubstituted or substituted aryl is alkenyl substituted with unsubstituted or substituted phenyl.
  • This phenyl in some embodiments, is substituted with alkoxy, such as methoxy, ethoxy, propoxy, or butoxy.
  • alkenyl substituted with unsubstituted or substituted heteroaryl is alkenyl substituted with a nitrogen-containing ring, oxygen-containing ring, or sulfur-containing ring.
  • Ri groups for thiazole esters suitable for use in compositions and methods of the invention include 2-thienyl; 4-pyridyl; 2-furyl; ⁇ -styryl; 1,2- dimethyl-4-pyrrolyl; and 3-indolyl. It should be appreciated that one skilled in the art, having read this specification, would understand that a heteroatom may be at any one of several positions in a ring.
  • Another thiazole ester suitable for use in compositions and methods of the invention is of the formula: or a salt or solvated salt thereof, in which A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-alanine-alanine, and the like), being blocked at the amino terminus by protecting groups known in the art, such as, for example, benzyloxycarbonyl, t-butoxycarbonyl, andjo-toluenesulfonyl; and R 2 is unsubstituted or substituted fused hydrocarbyl rings in which at least one ring is aromatic.
  • A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-
  • Fused hydrocarbyl rings include at least two hydrocarbyl rings that maintain at least one bond in common between the rings, for example, naphthyl, anthryl, 5,6,7,8-tetrahydronaphthyl, phenanthrenyl, triphenylenyl, lH-fluorenyl, and the like.
  • Fused hydrocarbyl rings may be substituted by, for example, aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO ⁇ , or hydroxy, in which such substituents may further be substituted by aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO H, or hydroxy. These substituents are as defined above.
  • fused hydrocarbyl rings contain at least one 5- membered ring. In other embodiments, fused hydrocarbyl rings contain at least one 6-membered ring. In still some embodiments, fused hydrocarbyl rings are substituted on at least one ring with alkyl, such as methyl, ethyl, propyl, or butyl. In other embodiments, fused hydrocarbyl rings are substituted on at least one ring with alkoxy, such as methoxy, ethoxy, propoxy, or butoxy. In one embodiment, R 2 is 1 -naphthyl.
  • Another thiazole ester suitable for use in compositions and methods of the invention is of the formula:
  • A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-alanine-alanine, and the like) being blocked at the amino terminus by protecting groups known in the art, such as, for example, benzyloxycarbonyl, t-butoxycarbonyl, and ?-toluene sulfonyl; and R 3 and R are each independently hydrogen, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxy, amino, unsubstituted or substituted acyl, halo, nitro, cyano, -SO 3 H, or hydroxy, with the
  • R 3 and Ri groups may be further substituted by aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO 3 H, or hydroxy.
  • aryl aryl
  • alkyl alkenyl
  • alkoxy alkyl
  • amino amino
  • R 3 and t is methoxy, ethoxy, propoxy, or butoxy
  • A is an N-blocked alanine residue.
  • R 3 is hydrogen and R t is methoxy, ethoxy, propoxy, or butoxy.
  • methoxy may be substituted at the ortho position and the compound of formula III may be:
  • methoxy may be substituted at, for example, the para or the meta position and the compound of formula III may be:
  • a composition of the invention includes a thiazole ester of formula I, II, or III.
  • Such a composition may also include a diazonium salt such as 2-methoxy-4- morpholinobenzene diazonium chloride, zinc chloride double salt.
  • compositions of the invention may be free of salts known in the art to have an accelerating action.
  • salts that give an accelerating action include salts of monovalent and divalent cations of the alkali metals and alkaline earth metals, such as, for example, Li + , Na + , K + , and Mg "1-1" as well as their typical anions.
  • a diagnostic device suitable for detecting leukocytes in urine includes a substrate suitable for supporting a thiazole ester of the invention, such as, for example, filter paper, filtration membrane, and other inert carriers. These substrates are known in the art.
  • the diagnostic device also includes one or more thiazole esters of formula I, II, or III. This compound is included with the substrate by, for example, sedimenting the derivative onto the substrate.
  • a novel diagnostic device may be prepared by combining the thiazole ester, an accelerator, and a diazonium salt.
  • Accelerators suitable for use in compositions and methods of the invention are known in the art and include, for example, octanediol and decanol.
  • Diazonium salts suitable for use in compositions and methods of the invention are known in the art and include compounds that may be used for color- developing technology, such as, for example, l-diazo-8-naphtol-3,6-disulfonic acid, chloride, zinc chloride double salt; 6-diazo-l-naphtol-3-sulfonic acid, chloride double salt; and 2-methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt.
  • the diazonium salt used in accordance with the invention has no interaction with urobilinogen and/or bilirubin.
  • Methods for manufacturing a device according to this invention are known in the art.
  • a first solution containing boric acid and polyvinylpyrrolidone is deposited onto a substrate, such as a filter paper.
  • a second solution containing a thiazole ester of the invention and a diazonium salt, such as 2-methoxy-4- morpholinobenzene diazonium chloride, zinc chloride double salt is deposited onto the substrate.
  • Both solutions deposited onto the substrate may be free of a salt known in the art to have an accelerating action as described above.
  • a thiazolone derivative and an alanine or polyalanine derivative may be used as starting materials.
  • Thiazolones may be synthesized by reacting carboxymethyl thiobenzimidate hydrobromide and pyridine. As illustrated in the following scheme, the synthesis of a thiazole ester of the invention includes the reaction of a thiazolone derivative of the general formula (2), and an amino acid chloride of the general formula (3).
  • Methods of the invention include detecting the presence of leukocytes in urine.
  • a urine sample is contacted with a thiazole ester of the invention and a diazonium salt in the presence of an accelerator. If leukocytes are present, then a reaction between thiazolyl and the salt produces an azo dye having a violet color.
  • a method is directed to contacting a urine sample with a substrate, for example, filter paper, that has a first solution of boric acid and poly vinyl pyrrolidone deposited thereon and then a second solution of a thiazole ester of formula I, II, or III; a diazonium salt; and an accelerator deposited thereon. This method may be carried out free of an accelerating salt. When a urine sample containing leukocytes contacts such a substrate, then a violet color, which appears on the substrate, is observed.
  • N-(p- toluenesulfonyl)-alanine is first synthesized. 50.0 g ofp-toluenesulfonyl chloride was added to 100 ml of 90 °C toluene with stirring. The j-toluenesulfonyl chloride solution in toluene was slowly added to 25.0 g of L-alanine dissolved in 500 ml of IN NaOH cooled to 5 °C and stirred for 24 hours. The resulting aqueous layer is separated and cooled to below 5 °C and with the addition of concentrated hydrochloric acid, pH was adjusted to 1.5. After standing in the refrigerator for 3 to 4 hours, the white solid crystals, so formed, were filtered, twice washed with water, and dried.
  • the blocked starting material is next produced by reacting N-(p- toluenesulfonyl)-alanine and oxalyl chloride.
  • HC1 gas is bubbled through a solution of 10 g of 4-cyanopyridine and 50 g of mercaptoacetic acid in approximately 20 ml of ether and 30 ml of chloroform for 24 hours. During the reaction 30 ml of ether and 50 ml of chloroform are added. The crystallized product, so formed, is filtered, washed with a solvent system of 1 : 1 ether and chloroform, and dried.
  • HC1 gas was bubbled through a solution of 25 g of 1-naphthonitrile and 25 g of mercaptoacetic acid in approximately 150 ml chloroform for 24 hours.
  • the crystallized product, so formed, was filtered, washed with 200 ml chloroform, and dried.
  • HC1 gas was bubbled through a solution of 5 g of l,5-dimethyl-2- pyrrolecarbonitrile and 5 g of mercaptoacetic acid in approximately 50 ml of ether/chloroform (1 : 1) for 24 hours.
  • the crystallized product, so formed, was filtered, washed with 100 ml ether/chloroform (1:1), and dried.
  • HC1 gas is bubbled through a solution of 5 g of 3-cyanoindole and 5 g of mercaptoacetic acid in approximately 50 ml of ether/chloroform (1 :1) for 24 hours.
  • the crystallized product, so formed, is filtered, washed with 100 ml ether/chloroform (1 :1), and dried.
  • HCl gas was bubbled through a solution of 5 g of 2-furonitrile and 5 g of mercaptoacetic acid in approximately 50 ml of ether/chloroform (1 : 1) for 24 hours.
  • the crystallized product, so formed, was filtered, washed with 100 ml ether/chloroform (1:1), and dried.
  • HCl gas was bubbled through a solution of 25 g of cinnamonitrile and 25 g of mercaptoacetic acid in approximately 150 ml of ether/chloroform (1 :1) for 24 hours.
  • the crystallized product, so formed, was filtered, washed with 200 ml ether/chloroform (1:1), and dried.
  • HCl gas was bubbled through a solution of 11 g of 3 -methoxy benzonitrile and 10 g of mercaptoacetic acid in approximately 75 ml of ether for 24 hours.
  • the crystallized product, so formed, was filtered, washed with 200 ml ether, and dried.
  • the residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried.
  • the product was identified by a proton NMR analysis. A sample of the product was dissolved in acetone- ⁇ (19mg/0.7 ml) and a proton spectrum was collected following AMRI SOP INS-041 using a Bruker® 300 MHz NMR Spectrometer (Bruker-Physik AG, Germany). The identity of the product was further confirmed by infrared spectral analysis by first mixing 263 mg of potassium bromide with 1.7 mg of the product and then grinding them in a Wig L Bug® (Crescent Dental Manufacturing Co., Illinois). The ground mixture was pressed into a disk and an infrared spectrum was collected by a Spectrum 1000 IR Spectrometer following AMRI SOP INS-026. The sample was scanned between 4000 and 400 cm -1 .
  • the residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried.
  • the identity of the product was further confirmed by infrared spectral analysis by first mixing 204 mg of potassium bromide with 1.3 mg of the product and then grinding them in a Wig L Bug® (Crescent Dental Manufacturing Co., Illinois). The ground mixture was pressed into a disk and an infrared spectrum was collected by a Spectrum 1000 IR Spectrometer following AMRI SOP INS-026. The sample was scanned between 4000 and 400 cm -1
  • the product was identified by two proton NMR analyses. For the first analysis, a sample of the product was dissolved in acetone-c? 6 (1 lmg/0.7 ml) and a proton spectrum was collected following AMRI SOP INS-041 using a Bruker® 300 MHz NMR Spectrometer (Bruker-Physik AG, Germany). For the second analysis, a proton spectrum was collected using a Bruker® 500 MHz NMR Spectrometer. The identity of the product was further confirmed by infrared spectral analysis by first mixing 235 mg of potassium bromide with 2.4 mg of the product and then grinding them in a Wig L Bug® (Crescent Dental Manufacturing Co., Illinois). The ground mixture was pressed into a disk and an infrared spectrum was collected by a Spectrum 1000 IR Spectrometer following AMRI SOP INS-026. The sample was scanned between 4000 and 400 cm -1 .
  • EXAMPLE 21 Preparation of a Leukocyte Diagnostic Device
  • a test strip containing a compound of the invention was prepared.
  • a small type of testing paper in a regular square was attached to the end of a polystyrene strip, sedimented, and dried with the following two mixing solutions successively.
  • the first solution 100 ml of aqueous solution
  • K-10 polyvinyl pyrrolidone
  • a second solution (100 ml of acetone) contained 0.06% (w/v) of 2— (2- thienyl)-4-(N-tosyl-L-alanyloxy) thiazol or 2-( ⁇ -styryl)-4-(N-tosyl-L- alanyloxy) thiazol; 0.05% (w/v) 2-methoxy-4-morpholinobenzene diazonium chloride zinc chloride disalts and 1.0% (w/v) n-decanol.
  • the sedimented paper was dried by heating at 50° C for 5 minutes.
  • Each assay was conducted by contacting a test strip (manufactured as described above) with a urine sample.
  • the test strip showed the appearance of a violet color.
  • the initial tint of violet color appeared within about 10 seconds and gradually darkened until the reaction was complete, which was about 1 minute.
  • the completed reaction showed a degree of color change that was suitable not only for identifying whether leukocytes were present in the urine sample but also for semiquantitatively determining the concentration of the leukocytes present.
  • EXAMPLE 22 Preparation of a Leukocyte Diagnostic Device
  • a test strip containing a composition of the invention is prepared.
  • a small type of testing paper in a regular square is attached to the end of a polystyrene strip, sedimented, and dried with the following two mixing solutions successively.
  • the first solution 100 ml of aqueous solution
  • K-10 polyvinyl pyrrolidone
  • a second solution (100 ml of acetone) contains 0.06% (w/v) of 2-(4-pyridyl)-4-(N- tosyl-L-alanyloxy) thiazol; 2-(l-naphthyl)-4-(N-tosyl-L-alanyloxy) thiazole; 2- (1 ,2-dimethyl-4-pyrrolyl)-4-(N-tosyl-L-alanyloxy) thiazol; 2-(2-furyl) -4-(N- tosyl-L-alanyloxy) thiazol; or 2-(3-indolyl)-4-(N-tosyl-L-alanyloxy) thiazol; 0.05% (w/v) 2-methoxy-4-morpholinobenzene diazonium chloride zinc chloride disalts and 1.0% (w/v) n-decanol.
  • the sedimented paper is dried by heating at 50° C for 5
  • Each assay is conducted by contacting a test strip (manufactured as described above) with a urine sample.
  • the test strip shows the appearance of a violet color.
  • the initial tint of violet color appears within about 10 seconds and gradually darkens until the reaction is complete, which is about 1 minute.
  • the completed reaction shows a degree of color change that is suitable not only for identifying whether leukocytes are present in the urine sample but also for semiquantitatively determining the concentration of the leukocytes.
  • a test strip containing a compound of the invention was prepared.
  • a small type of testing paper in a regular square was attached to the end of a polystyrene strip, sedimented, and dried with the following two mixing solutions successively.
  • the first solution 100 ml of aqueous solution
  • K-10 polyvinyl pyrrolidone
  • a second solution (100 ml of acetone) contained 0.06% (w/v) of 2-(3- methoxyphenyl)-4-(N-tosyl-L-alanyloxy) thiazole or 2-(2-methoxyphenyl)-4- (N-tosyl-L-alanyloxy) thiazole; 0.05% (w/v) 2-methoxy-4-morpholinobenzene diazonium chloride zinc chloride disalts and 1.0% (w/v) n-decanol.
  • the sedimented paper was dried by heating at 50° C for 5 minutes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Thiazole esters are suitable for detecting the presence of leukocytes in urine. Such thiazole esters are suitable for use in compositions, diagnostic devices, and methods for detecting the presence of leukocytes. In one embodiment, a thiazole ester is of formula (I) or a salt or solvated salt thereof, in which A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine; and R1 is unsubstituted or substituted heteroaryl; alkenyl substituted with unsubstituted or substituted aryl; or alkenyl substituted with unsubstituted or substituted heteroaryl. For example, R1 may be thienyl, pyridyl, furyl, styryl, pyrrolyl, or indolyl. In still another embodiment, the thiazole ester includes unsubstituted or substituted fused hydrocarbyl rings as a substituent. In one embodiment, fused hydrocarbyl rings include naphthyl. In another embodiment, fused hydrocarbyl rings include anthryl.

Description

COMPOSITION AND DEVICE FOR DETECTING LEUKOCYTES
IN URINE
Field of the Invention
This invention relates generally to compounds, compositions, devices, and methods useful for detecting the presence of leukocytes through the activity of leukocyte esterases and proteinases in urine.
Background of the Invention
The presence of leukocytes in human urine is associated with infection or malfunction in the kidney or urinary tract. Accurate detection has a significant meaning for the physiological treatment or diagnosis of the patient.
A basic method to measure the number of leukocytes in urine by microscope has been widely available for some time. However, the disadvantages of this method include the investment of time and money in obtaining and installing the appropriate instrumentation. Further, false negatives can be obtained when samples are allowed to sit too long before analysis.
Research has been directed to developing other methods, such as indicator assays, that are suitable for detecting leukocytes more easily, conveniently, and accurately. Typical indicator assays use a specific chemical substance (e.g., a substrate) that is degraded by one or more enzymes present in leukocytes to create a product suitable for effectuating a visible color change.
One such leukocyte assay is disclosed in U.S. Patent No. 3,087,794 and involves the use of peroxidase that is contained in a granular leukocyte. This assay includes a filter paper stained with hydrogen peroxide and ø-tolidine, which shows a colored oxidative product when contacted with leukocytes. Yet this assay is less than desirable because peroxidase can be dangerous and reductive materials in urine may make actual application impractical. Other methods designed to confirm the presence of esterase and proteinase in leukocytes have also been developed. For example, one method uses a colorless or pale-colored ester compound as a substrate that is degraded by esterase into a colorless acid moiety and an alcoholic moiety. Then, under diazonium or oxidative reaction, the alcoholic moiety is converted to a second densely colored product. This method was derived from a process in which enzymatic degradation of the substrate naphtol-AS-D chloroacetate produced chloroacetate and naphtol-AS. Reaction of the naphtol-AS product with a diazonium salt resulted in the formation of a colored azo compound.
This assay allows for the determination of leukocyte concentration by the naked eye. Yet the use of this assay is less than desirable because the diazonium salt may react with urobilinogen or bilirubin contained in urine. As a result, concentrations of leukocytes greater than 500 cells/μl are often necessary to avoid a false-negative reading.
U.K. Patent No. 1,128,371 discloses other possible substrates, i.e., colorless indoxyl or thioindoxylesters. These substrates are degraded into indoxyl or thioindoxyl by esterase. Colored indigo or thioindigo may then be produced by reaction with oxygen in the air or by an oxidizer. Yet the use of an assay with these substrates is less than desirable because this is not sensitive and fails to detect leukocytes at a concentration less than 10,000 cells/μl.
Similarly, U.S. Patent No. 4,278,763 suggests indoxyl-type substrates by disclosing a method of using indoxyl or thioindoxylamino acid ester as a substrate.
Other assays using pyrrole derivatives as substrates have also been disclosed. For example, U.S. Patent No. 4,704,460 discloses use of an amino acid ester of a pyrrole derivative as a substrate. When this derivative is degraded in the presence of diazonium salt, a change in sample color to deep violet results. Moreover, the addition of a nucleophilic alcohol, such as decanol, greatly facilitates reaction rate, and in turn, allows detection of leukocyte concentrations as low as 10 cells/μl within 90 seconds. Yet this assay is less than desirable because the syntheses of these two substrates is very difficult.
The above-described assays are characterized by numerous disadvantages. Some disadvantages include the detection of false negatives, the interference of urobilinogen or bilirubin, the lack of sensitivity, and the requirement of less-than- desirable substrates. Thus, it would be desirable to identify new compounds and methods of using the compounds to detect the presence of leukocytes in urine.
Summary of the Invention
The invention is directed to thiazole esters suitable for detecting leukocytes in urine, compositions containing thiazole esters, diagnostic devices suitable for detecting leukocytes in urine, and methods of using the thiazole esters or compositions thereof for detecting leukocytes in urine. In one aspect, this invention is directed to novel thiazole esters. One thiazole ester according to this invention is of the formula:
Figure imgf000005_0001
or a salt or solvated salt thereof, in which
A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine; and
Ri is unsubstituted or substituted heteroaryl; alkenyl substituted with unsubstituted or substituted aryl; or alkenyl substituted with unsubstituted or substituted heteroaryl. For example, Ri may be thienyl, pyridyl, furyl, styryl, pyrrolyl, or indolyl.
Another thiazole ester according to this invention is of the formula:
Figure imgf000005_0002
or a salt or solvated salt thereof, in which
A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine; and
R2 is unsubstituted or substituted fused hydrocarbyl rings in which at least one ring is aromatic. For example, R2 may be naphthyl or anthryl.
Another thiazole ester according to this invention is of the formula:
Figure imgf000005_0003
or a salt or solvated salt thereof, in which
A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine; and R3 and Rt are each independently hydrogen, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxy, amino, unsubstituted or substituted acyl, halo, nitro, cyano. -SO H, or hydroxy, with the proviso that R3 and R4 are not both hydrogen.
In another aspect, this invention is directed to compositions that include a thiazole ester of formula I, II, or III. Compositions of the invention may also include a diazonium salt such as 2-methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt. In still another aspect, this invention is directed to diagnostic devices that include a compound or composition of the invention. Such diagnostic devices include a substrate having a thiazole ester of formula I, II, or III deposited thereon.
The compounds, compositions, and diagnostic devices of the invention are also suitable for use in methods for detecting leukocytes in urine. Methods for detecting leukocytes in urine include contacting a thiazole ester of the invention and a diazonium salt with a urine sample.
The compounds and compositions suitable for use in devices and methods of the invention are typically pharmaceutically acceptable.
The compositions, diagnostic devices, and methods of the invention can be free of accelerating salt.
DETAILED DESCRIPTION OF THE INVENTION The invention is directed to detecting leukocytes in urine. The presence of leukocytes is typically detected by detecting the presence of enzymes known in the art as leukocyte esterases and leukocyte proteinases that are present with leukocytes. Compounds of the invention include thiazole esters that contain an ester functionality, which is hydrolyzed upon exposure to leukocytes in urine. The hydrolysis of the ester of a thiazole ester of the invention provides a useful diagnostic technique because thiazolyl can react with a diazonium salt to produce an azo dye.
The compounds according to this invention are thiazole esters that are suitable for use in compositions, diagnostic devices, and methods that can be used to detect leukocytes in urine.
One thiazole ester suitable for use in compositions and methods of the invention is of the formula:
Figure imgf000007_0001
or a salt or solvated salt thereof, in which A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-alanine-alanine, and the like), being blocked at the amino terminus by protecting groups known in the art, such as, for example, benzyloxycarbonyl, t-butoxycarbonyl, and -toluenesulfonyl; and Ri is unsubstituted or substituted heteroaryl; alkenyl substituted with unsubstituted or substituted aryl; or alkenyl substituted with unsubstituted or substituted heteroaryl. The term "heteroaryl" includes heterocyclic aromatic derivatives having at least one heteroatom, such as, for example, nitrogen, oxygen, phosphorus, or sulfur, and includes, for example, furyl, pyrrolyl, thienyl, oxazolyl, pyridyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, and the like. The term "heteroaryl" also includes fused rings in which at least one ring is aromatic, such as, for example, indolyl, purinyl, benzofuryl, benzothienyl, quinolyl, 4,5,6,7-tetrahydro-lH-indolyl, and the like. In the case of fused rings that have a hydrocarbyl ring fused to a heterocyclic ring, such as, for example, benzothienyl and indolyl, the fused rings may be bonded to thiazolyl through either the hydrocarbyl ring or the heterocyclic ring. In some embodiments, heteroaryl includes a 5-membered ring. In other embodiments, heteroaryl includes a 6-membered ring. Such heteroaryl groups may be unsubstituted or substituted on the ring by, for example, aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO3Η, or hydroxy, in which such substituents may further be substituted by aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO3H, or hydroxy. In some embodiments, heteroaryl is substituted with alkyl, such as methyl, ethyl, propyl, or butyl. In other embodiments, heteroaryl is substituted with alkoxy, such as methoxy, ethoxy, propoxy, or butoxy. In still other embodiments, heteroaryl is substituted with aryl or heteroaryl.
The term "aryl" includes aromatic hydrocarbyl, such as, for example, phenyl, including fused aromatic rings, such as, for example, naphthyl, anthryl, and the like. The term "alkyl" includes a straight or branched saturated aliphatic hydrocarbon chain having from 1 to 4 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, t-butyl (1,1-dimethylethyl), and the like. The term "alkenyl" includes an unsaturated aliphatic hydrocarbon chain having from 2 to 4 carbon atoms, such as, for example, ethenyl, 1-propenyl, 2- propenyl, 1-butenyl, 2-methyl- 1-propenyl, and the like.
The above alkyl or alkenyl groups may optionally be interrupted in the chain by a heteroatom, such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.
The term "alkoxy" includes alkyl as defined above joined to an oxygen atom having from 1 to 4 carbon atoms in a straight or branched chain, such as, for example, methoxy, ethoxy, propoxy, isopropoxy (1-methylethoxy), butoxy, t- butoxy (1,1-dimethylethoxy), and the like.
The term "amino" includes a substituent of the formula -N(R5)2 in which each R5 is independently hydrogen or alkyl. The term "alkyl" is as defined above.
The term "alkenyl substituted with unsubstituted or unsubstituted aryl" or "alkenyl substituted with unsubstituted or substituted heteroaryl" includes alkenyl as defined above, and such groups are substituted with unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl, respectively. The terms "aryl" and "heteroaryl" are as defined above. Examples of suitable substituted alkenyls include styryl, cinnamyl, furylethenyl, pyridylethenyl, andthienylpropenyl. In some embodiments, alkenyl substituted with unsubstituted or substituted aryl is alkenyl substituted with unsubstituted or substituted phenyl. This phenyl, in some embodiments, is substituted with alkoxy, such as methoxy, ethoxy, propoxy, or butoxy. In other embodiments, alkenyl substituted with unsubstituted or substituted heteroaryl is alkenyl substituted with a nitrogen-containing ring, oxygen-containing ring, or sulfur-containing ring.
Examples of Ri groups for thiazole esters suitable for use in compositions and methods of the invention include 2-thienyl; 4-pyridyl; 2-furyl; β-styryl; 1,2- dimethyl-4-pyrrolyl; and 3-indolyl. It should be appreciated that one skilled in the art, having read this specification, would understand that a heteroatom may be at any one of several positions in a ring.
Another thiazole ester suitable for use in compositions and methods of the invention is of the formula:
Figure imgf000009_0001
or a salt or solvated salt thereof, in which A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-alanine-alanine, and the like), being blocked at the amino terminus by protecting groups known in the art, such as, for example, benzyloxycarbonyl, t-butoxycarbonyl, andjo-toluenesulfonyl; and R2 is unsubstituted or substituted fused hydrocarbyl rings in which at least one ring is aromatic.
Fused hydrocarbyl rings include at least two hydrocarbyl rings that maintain at least one bond in common between the rings, for example, naphthyl, anthryl, 5,6,7,8-tetrahydronaphthyl, phenanthrenyl, triphenylenyl, lH-fluorenyl, and the like. Fused hydrocarbyl rings may be substituted by, for example, aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO Η, or hydroxy, in which such substituents may further be substituted by aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO H, or hydroxy. These substituents are as defined above.
In some embodiments, fused hydrocarbyl rings contain at least one 5- membered ring. In other embodiments, fused hydrocarbyl rings contain at least one 6-membered ring. In still some embodiments, fused hydrocarbyl rings are substituted on at least one ring with alkyl, such as methyl, ethyl, propyl, or butyl. In other embodiments, fused hydrocarbyl rings are substituted on at least one ring with alkoxy, such as methoxy, ethoxy, propoxy, or butoxy. In one embodiment, R2 is 1 -naphthyl.
Another thiazole ester suitable for use in compositions and methods of the invention is of the formula:
Figure imgf000009_0002
or a salt or solvated salt thereof, in which A is an N-blocked amino acid residue or an N-blocked peptide chain, preferably N-blocked alanine or N-blocked polyalanine (e.g., alanine-alanine, alanine-alanine-alanine, and the like) being blocked at the amino terminus by protecting groups known in the art, such as, for example, benzyloxycarbonyl, t-butoxycarbonyl, and ?-toluene sulfonyl; and R3 and R are each independently hydrogen, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxy, amino, unsubstituted or substituted acyl, halo, nitro, cyano, -SO3H, or hydroxy, with the proviso that R3 and R are not both hydrogen.
Any substituted R3 and Ri groups may be further substituted by aryl, heteroaryl, alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, -SO3H, or hydroxy.
The terms "aryl," "heteroaryl," "alkyl," "alkenyl," "alkoxy," and "amino" are as defined above.
In one embodiment, at least one of R3 and t is methoxy, ethoxy, propoxy, or butoxy, and A is an N-blocked alanine residue. In another embodiment, R3 is hydrogen and Rt is methoxy, ethoxy, propoxy, or butoxy. For example, methoxy may be substituted at the ortho position and the compound of formula III may be:
Figure imgf000010_0001
Alternatively, methoxy may be substituted at, for example, the para or the meta position and the compound of formula III may be:
Figure imgf000010_0002
A composition of the invention includes a thiazole ester of formula I, II, or III. Such a composition may also include a diazonium salt such as 2-methoxy-4- morpholinobenzene diazonium chloride, zinc chloride double salt.
Compositions of the invention may be free of salts known in the art to have an accelerating action. Examples of salts that give an accelerating action include salts of monovalent and divalent cations of the alkali metals and alkaline earth metals, such as, for example, Li+, Na+, K+, and Mg"1-1" as well as their typical anions.
A diagnostic device suitable for detecting leukocytes in urine includes a substrate suitable for supporting a thiazole ester of the invention, such as, for example, filter paper, filtration membrane, and other inert carriers. These substrates are known in the art. The diagnostic device also includes one or more thiazole esters of formula I, II, or III. This compound is included with the substrate by, for example, sedimenting the derivative onto the substrate.
Generally, a novel diagnostic device may be prepared by combining the thiazole ester, an accelerator, and a diazonium salt. Accelerators suitable for use in compositions and methods of the invention are known in the art and include, for example, octanediol and decanol.
Diazonium salts suitable for use in compositions and methods of the invention are known in the art and include compounds that may be used for color- developing technology, such as, for example, l-diazo-8-naphtol-3,6-disulfonic acid, chloride, zinc chloride double salt; 6-diazo-l-naphtol-3-sulfonic acid, chloride double salt; and 2-methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt. Preferably, the diazonium salt used in accordance with the invention has no interaction with urobilinogen and/or bilirubin. Methods for manufacturing a device according to this invention are known in the art. Generally, a first solution containing boric acid and polyvinylpyrrolidone is deposited onto a substrate, such as a filter paper. Then a second solution containing a thiazole ester of the invention and a diazonium salt, such as 2-methoxy-4- morpholinobenzene diazonium chloride, zinc chloride double salt, is deposited onto the substrate. Both solutions deposited onto the substrate may be free of a salt known in the art to have an accelerating action as described above.
To prepare a thiazole ester of the invention, a thiazolone derivative and an alanine or polyalanine derivative may be used as starting materials. Thiazolones may be synthesized by reacting carboxymethyl thiobenzimidate hydrobromide and pyridine. As illustrated in the following scheme, the synthesis of a thiazole ester of the invention includes the reaction of a thiazolone derivative of the general formula (2), and an amino acid chloride of the general formula (3).
Figure imgf000012_0001
(2) (3) (i)
Each starting material is dissolved in solvent, and the resulting solutions are cooled and mixed slowly. This reaction mixture is stirred and then allowed to stand at room temperature for several hours. The reaction mixture is then washed, dried, filtered, and concentrated under reduced pressure. The solid, so formed, is dissolved in acetone and hexane is added. To remove any resulting hemisolid impurity, the reaction mixture is allowed to stand at low temperature for about 1 hour. Another portion of hexane is added to the residue and the mixture is refrigerated for 10 hours. The desired product is then filtered and dried. Thiazolone derivatives tend to be highly reactive, resulting in dimerization or multimerization even during recrystallization. This may lead to poor yield. Thus, for the current invention, pure substances are isolated from the final product of the synthesis of the thiazole ester without purifying thiazolone of the general formula (2). This method of synthesis enhances the yield of the derivatives of the invention. In contrast to this, the aforementioned indole or pyrrole derivatives have some recognized disadvantages. Many side reactions occur in the process of manufacturing their intermediates. Moreover, the reaction mechanism is very complicated and the yield for indole and pyrrole derivatives proves to be poor. But the synthesis of the thiazole esters of this invention allows for larger amounts of final product to be produced by a general method within a relatively short period of time. Moreover, because the method of synthesizing the thiazole esters of the invention is relatively simple and general, mass-scale production is more practical.
Methods of the invention include detecting the presence of leukocytes in urine. To detect the presence of leukocytes in urine, a urine sample is contacted with a thiazole ester of the invention and a diazonium salt in the presence of an accelerator. If leukocytes are present, then a reaction between thiazolyl and the salt produces an azo dye having a violet color. Typically such a method is directed to contacting a urine sample with a substrate, for example, filter paper, that has a first solution of boric acid and poly vinyl pyrrolidone deposited thereon and then a second solution of a thiazole ester of formula I, II, or III; a diazonium salt; and an accelerator deposited thereon. This method may be carried out free of an accelerating salt. When a urine sample containing leukocytes contacts such a substrate, then a violet color, which appears on the substrate, is observed.
WORKING EXAMPLES This invention will be further characterized by the following examples.
These examples are not meant to limit the scope of the invention, which has been fully set forth in the foregoing description. Variations within the scope of the invention are apparent to those skilled in the art.
EXAMPLE 1
N-(p-Toluenesulfonyl)-alanine
Figure imgf000013_0001
To synthesize a starting material containing a blocked N-alanine, N-(p- toluenesulfonyl)-alanine is first synthesized. 50.0 g ofp-toluenesulfonyl chloride was added to 100 ml of 90 °C toluene with stirring. The j-toluenesulfonyl chloride solution in toluene was slowly added to 25.0 g of L-alanine dissolved in 500 ml of IN NaOH cooled to 5 °C and stirred for 24 hours. The resulting aqueous layer is separated and cooled to below 5 °C and with the addition of concentrated hydrochloric acid, pH was adjusted to 1.5. After standing in the refrigerator for 3 to 4 hours, the white solid crystals, so formed, were filtered, twice washed with water, and dried.
EXAMPLE 2 N-Tosyl-L-alanyl chloride
Figure imgf000013_0002
The blocked starting material is next produced by reacting N-(p- toluenesulfonyl)-alanine and oxalyl chloride.
30.0 g of N-(p-toluenesulfonyl)-alanine and 6 to 7 drops of DMF (dimethylformamide) were dissolved in 100 ml of dichloromethane and 5 ml of oxalyl chloride was added dropwise. After stirring for 3 hours at room temperature the reaction mixture was evaporated down to a residue which was dissolved in 100 ml of dichloromethane. The dichloromethane was again evaporated and the resulting residue dissolved in 50 ml of dichloromethane followed by the addition of 100 ml hexane. After standing in the refrigerator overnight the crystals, so formed, were filtered and dried.
EXAMPLE 3 2-(4-Pyridyl)-4-thiazol
Figure imgf000014_0001
HC1 gas is bubbled through a solution of 10 g of 4-cyanopyridine and 50 g of mercaptoacetic acid in approximately 20 ml of ether and 30 ml of chloroform for 24 hours. During the reaction 30 ml of ether and 50 ml of chloroform are added. The crystallized product, so formed, is filtered, washed with a solvent system of 1 : 1 ether and chloroform, and dried.
EXAMPLE 4 2-(2-Thienyl)-4-thiazol
Figure imgf000014_0002
HC1 gas was bubbled through a solution of 10 g of 3-thiophenecarbonitrile and 35 g of mercaptoacetic acid in approximately 50 ml of ether for 24 hours. The crystallized product, so formed, was filtered, washed with 200 ml ether, and dried. EXAMPLE 5 2-( 1 -Naphthyl)-4-thiazol
Figure imgf000015_0001
HC1 gas was bubbled through a solution of 25 g of 1-naphthonitrile and 25 g of mercaptoacetic acid in approximately 150 ml chloroform for 24 hours. The crystallized product, so formed, was filtered, washed with 200 ml chloroform, and dried.
EXAMPLE 6 2-( 1 ,2-Dimethyl-4-pyrrolyl)-4-thiazol
Figure imgf000015_0002
HC1 gas was bubbled through a solution of 5 g of l,5-dimethyl-2- pyrrolecarbonitrile and 5 g of mercaptoacetic acid in approximately 50 ml of ether/chloroform (1 : 1) for 24 hours. The crystallized product, so formed, was filtered, washed with 100 ml ether/chloroform (1:1), and dried.
EXAMPLE 7 2-(3-Indolyl)-4-thiazol
Figure imgf000015_0003
HC1 gas is bubbled through a solution of 5 g of 3-cyanoindole and 5 g of mercaptoacetic acid in approximately 50 ml of ether/chloroform (1 :1) for 24 hours. The crystallized product, so formed, is filtered, washed with 100 ml ether/chloroform (1 :1), and dried.
EXAMPLE 8 2-(2-Furyl)-4-thiazol
Figure imgf000016_0001
HCl gas was bubbled through a solution of 5 g of 2-furonitrile and 5 g of mercaptoacetic acid in approximately 50 ml of ether/chloroform (1 : 1) for 24 hours. The crystallized product, so formed, was filtered, washed with 100 ml ether/chloroform (1:1), and dried.
EXAMPLE 9 2-(β-Styryl)-4-thiazol
Figure imgf000016_0002
HCl gas was bubbled through a solution of 25 g of cinnamonitrile and 25 g of mercaptoacetic acid in approximately 150 ml of ether/chloroform (1 :1) for 24 hours. The crystallized product, so formed, was filtered, washed with 200 ml ether/chloroform (1:1), and dried.
EXAMPLE 10 2-(3-Methoxyphenyl)-4-thiazol
Figure imgf000016_0003
HCl gas was bubbled through a solution of 11 g of 3 -methoxy benzonitrile and 10 g of mercaptoacetic acid in approximately 75 ml of ether for 24 hours. The crystallized product, so formed, was filtered, washed with 200 ml ether, and dried.
EXAMPLE 11 2-(2-Methoxyphenyl)-4-thiazol
Figure imgf000017_0001
Using the method of Example 10, 2-methoxybenzonitrile and mercaptoacetic acid were mixed. The recovered product is shown above.
EXAMPLE 12 2-(4-Pyridyl)-4-(N-tosyl-L-alanyloxy)thiazol
Figure imgf000017_0002
5.0 g of 2-(4-pyridyl)-4-thiazol is dissolved in acosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N- tosyl-L-alanyl chloride in 50 ml dichloromethane is then added dropwise to the above mixture. The reaction solution is stirred at room temperature or until the reaction is complete. The solution is washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried.
EXAMPLE 13 2-(2-Thienyl)-4-(N-tosyl-L-alanyloxy)thiazol
Figure imgf000018_0001
5.0 g of 2-(3-thienyl)-4-thiazol was dissolved in a cosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N- tosyl-L-alanyl chloride in 50 ml dichloromethane was then added dropwise to the above mixture. The reaction solution was stirred at room temperature until the reaction was complete. The solution was washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, was dissolved in 100 ml of acteone and 100 ml of hexane was added. After standing in the refrigerator for 1 hour, dark semisolid impurities were decanted off and the remaining solvent evaporated. The amorphous solid, so formed, was dissolved in a minimum of ethylacetate, the resulting solution applied to a silica column and eluted with a 2:1 ethylacetate/hexane solvent system. Fractions containing the desired product were collected, the solvent was evaporated, and the resulting residue was dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, was filtered and dried.
The product was identified by a proton NMR analysis. A sample of the product was dissolved in acetone-^ (19mg/0.7 ml) and a proton spectrum was collected following AMRI SOP INS-041 using a Bruker® 300 MHz NMR Spectrometer (Bruker-Physik AG, Germany). The identity of the product was further confirmed by infrared spectral analysis by first mixing 263 mg of potassium bromide with 1.7 mg of the product and then grinding them in a Wig L Bug® (Crescent Dental Manufacturing Co., Illinois). The ground mixture was pressed into a disk and an infrared spectrum was collected by a Spectrum 1000 IR Spectrometer following AMRI SOP INS-026. The sample was scanned between 4000 and 400 cm-1.
EXAMPLE 14 2-( 1 -Naphthyl)-4-(N-tosyl-L-alanyloxy) thiazol
Figure imgf000019_0001
5.0 g of 2-(l-naphthyl)-4-thiazol is dissolved in a cosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N- tosyl-L-alanyl chloride in 50 ml dichloromethane is then added dropwise to the above mixture. The reaction solution is stirred at room temperature until the reaction is complete. The solution is washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2:1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried. EXAMPLE 15 2-(l ,2-Dimethyl-4-pyrrolyl)-4-(N-tosyl-L-alanyloxy) thiazol
Figure imgf000020_0001
5.0 g of 2-(l,2-dimethyl-4-pyrrolyl)-4-thiazol is dissolved in acosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N-tosyl-L-alanyl chloride in 50 ml dichloromethane is then added dropwise to the above mixture. The reaction solution is stirred at room temperature or until the reaction is complete. The solution is washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2:1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried. EXAMPLE 16 2-(3-Indolyl)-4-(N-tosyl-L-alanyloxyXhiazol
Figure imgf000021_0001
5.0 g of 2-(3-indolyl)-4-thiazol is dissolved in a cosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N- tosyl-L-alanyl chloride in 50 ml dichloromethane is then added dropwise to the above mixture. The reaction solution is stirred at room temperature until the reaction is complete. The solution is washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried. EXAMPLE 17 2-(2-Furyl)-4-(N-tosyl-L-alanyloxy)thiazol
Figure imgf000022_0001
5.0 g of 2-(2-furyl)-4-thiazol is dissolved in a cosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N- tosyl-L-alanyl chloride in 50 ml dichloromethane is then added dropwise to the above mixture. The reaction solution is stirred at room temperature until the reaction is complete. The solution is washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, is dissolved in 100 ml of acteone and 100 ml of hexane is added. After standing in the refrigerator for 1 hour, dark semisolid impurities are decanted off and the remaining solvent evaporated. The amorphous solid, so formed, is dissolved in a minimum of ethylacetate, the resulting solution is then applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system. Fractions containing the desired product are collected, the solvent is evaporated, and the resulting residue is dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, is filtered and dried.
EXAMPLE 18 2-(β-Styryl)-4-(N-tosyl-L-alanyloxy)thiazol
Figure imgf000023_0001
5.0 g of 2-(β-styryl)-4-thiazol was dissolved in a cosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N- tosyl-L-alanyl chloride in 50 ml dichloromethane was then added dropwise to the above mixture. The reaction solution was stirred at room temperature until the reaction was complete. The solution was washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, was dissolved in 100 ml of acteone and 100 ml of hexane was added. After standing in the refrigerator for 1 hour, dark semisolid impurities were decanted off and the remaining solvent evaporated. The amorphous solid, so formed, was dissolved in a minimum of ethylacetate, the resulting solution applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system. Fractions containing the desired product were collected, the solvent was evaporated, and the resulting residue was dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the product, so formed, was filtered and dried.
EXAMPLE 19 2-(3-Methoxyphenyl)-4-(N-tosyl-L-alanyloxy)thiazol
Figure imgf000024_0001
5.0 g of 2-(3-methoxyphenyl)-4-thiazol was dissolved in a cosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N-tosyl-L-alanyl chloride in dichloromethane was then added dropwise to the above mixture. The reaction solution was stirred at room temperature until the reaction was complete. The solution was washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, was dissolved in 100 ml of acetone and 100 ml of hexane were added. After standing in the refrigerator for 1 hour, dark semisolid impurities were decanted off and the remaining solvent evaporated. The amorphous solid, so formed, was dissolved in a minimum of ethylacetate, the resulting solution applied to a silica column and eluted with a 2: 1 ethylacetate/hexane solvent system.
Fractions containing the desired product were collected, the solvent was evaporated, and the resulting residue was dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the white crystals, so formed, were filtered and dried. The product was identified by proton NMR analysis by dissolving a sample of the product in acetone-< (15mg/0.7 ml) and collecting a proton spectrum following AMRI SOP LNS-041 using a Bruker® 300 MHz NMR Spectrometer (Bruker-Physik AG, Germany).
The identity of the product was further confirmed by infrared spectral analysis by first mixing 204 mg of potassium bromide with 1.3 mg of the product and then grinding them in a Wig L Bug® (Crescent Dental Manufacturing Co., Illinois). The ground mixture was pressed into a disk and an infrared spectrum was collected by a Spectrum 1000 IR Spectrometer following AMRI SOP INS-026. The sample was scanned between 4000 and 400 cm -1
EXAMPLE 20 2-(2-Methoxyphenyl)-4-(N-tosyl-L-alanyloxy)thiazol
Figure imgf000025_0001
5.0 g of 2-(2-methoxyphenyl)-4-thiazol was dissolved in acosolvent of 100 ml of dichloromethane and 10 ml pyridine and cooled to 5 °C. A solution of 15.0 g of N-tosyl-L-alanyl chloride in dichloromethane was then added dropwise to the above mixture. The reaction solution was stirred at room temperature for four hours or until the reaction was complete. The solution was washed with IN hydrochloric acid, water, saturated sodium bicarbonate, and a saturated sodium chloride solution in that order; dried over magnesium sulfonate; filtered; and concentrated under reduced pressure. The residue, so formed, was dissolved in 100 ml of acetone and 100 ml of hexane were added. After standing in the refrigerator for 1 hour, dark semisolid impurities were decanted off and the remaining solvent evaporated. The amorphous solid, so formed, was dissolved in a minimum of ethylacetate, the resulting solution applied to a silica column and eluted with a 2:1 ethylacetate/hexane solvent system. Fractions containing the desired product were collected, the solvent evaporated and the resulting residue was dissolved in 20 ml of acetone followed by the addition of 50 ml hexane. After standing in the refrigerator the white crystals, so formed, were filtered and dried.
The product was identified by two proton NMR analyses. For the first analysis, a sample of the product was dissolved in acetone-c?6 (1 lmg/0.7 ml) and a proton spectrum was collected following AMRI SOP INS-041 using a Bruker® 300 MHz NMR Spectrometer (Bruker-Physik AG, Germany). For the second analysis, a proton spectrum was collected using a Bruker® 500 MHz NMR Spectrometer. The identity of the product was further confirmed by infrared spectral analysis by first mixing 235 mg of potassium bromide with 2.4 mg of the product and then grinding them in a Wig L Bug® (Crescent Dental Manufacturing Co., Illinois). The ground mixture was pressed into a disk and an infrared spectrum was collected by a Spectrum 1000 IR Spectrometer following AMRI SOP INS-026. The sample was scanned between 4000 and 400 cm-1.
EXAMPLE 21 Preparation of a Leukocyte Diagnostic Device To detect the presence of leukocytes in urine, a test strip containing a compound of the invention was prepared. A small type of testing paper in a regular square was attached to the end of a polystyrene strip, sedimented, and dried with the following two mixing solutions successively. The first solution (100 ml of aqueous solution) contained 5% (w/v) boric acid (pH 7.7) and 2% (w/v) polyvinyl pyrrolidone (K-10). The sedimented paper was dried by heating at 60° C for 10 minutes. A second solution (100 ml of acetone) contained 0.06% (w/v) of 2— (2- thienyl)-4-(N-tosyl-L-alanyloxy) thiazol or 2-(β-styryl)-4-(N-tosyl-L- alanyloxy) thiazol; 0.05% (w/v) 2-methoxy-4-morpholinobenzene diazonium chloride zinc chloride disalts and 1.0% (w/v) n-decanol. The sedimented paper was dried by heating at 50° C for 5 minutes.
Successful leukocyte assays (i.e., the assays were useful for correctly identifying the presence of leukocytes in urine) were carried out using a diagnostic device that contained each one of the thiazole esters listed in this Example.
Each assay was conducted by contacting a test strip (manufactured as described above) with a urine sample. When the urine sample contained leukocytes, the test strip showed the appearance of a violet color. The initial tint of violet color appeared within about 10 seconds and gradually darkened until the reaction was complete, which was about 1 minute. The completed reaction showed a degree of color change that was suitable not only for identifying whether leukocytes were present in the urine sample but also for semiquantitatively determining the concentration of the leukocytes present.
EXAMPLE 22 Preparation of a Leukocyte Diagnostic Device To detect the presence of leukocytes in urine, a test strip containing a composition of the invention is prepared. A small type of testing paper in a regular square is attached to the end of a polystyrene strip, sedimented, and dried with the following two mixing solutions successively. The first solution (100 ml of aqueous solution) contains 5% (w/v) boric acid (pH 7.7) and 2% (w/v) polyvinyl pyrrolidone (K-10). The sedimented paper is dried by heating at 60° C for 10 minutes. A second solution (100 ml of acetone) contains 0.06% (w/v) of 2-(4-pyridyl)-4-(N- tosyl-L-alanyloxy) thiazol; 2-(l-naphthyl)-4-(N-tosyl-L-alanyloxy) thiazole; 2- (1 ,2-dimethyl-4-pyrrolyl)-4-(N-tosyl-L-alanyloxy) thiazol; 2-(2-furyl) -4-(N- tosyl-L-alanyloxy) thiazol; or 2-(3-indolyl)-4-(N-tosyl-L-alanyloxy) thiazol; 0.05% (w/v) 2-methoxy-4-morpholinobenzene diazonium chloride zinc chloride disalts and 1.0% (w/v) n-decanol. The sedimented paper is dried by heating at 50° C for 5 minutes.
Each assay is conducted by contacting a test strip (manufactured as described above) with a urine sample. When the urine sample contains leukocytes, the test strip shows the appearance of a violet color. The initial tint of violet color appears within about 10 seconds and gradually darkens until the reaction is complete, which is about 1 minute. The completed reaction shows a degree of color change that is suitable not only for identifying whether leukocytes are present in the urine sample but also for semiquantitatively determining the concentration of the leukocytes.
EXAMPLE 23 Preparation of a Leukocyte Diagnostic Device
To detect the presence of leukocytes in urine, a test strip containing a compound of the invention was prepared. A small type of testing paper in a regular square was attached to the end of a polystyrene strip, sedimented, and dried with the following two mixing solutions successively. The first solution (100 ml of aqueous solution) contained 5% (w/v) boric acid (pH 7.7) and 2% (w/v) polyvinyl pyrrolidone (K-10). The sedimented paper was dried by heating at 60° C for 10 minutes. A second solution (100 ml of acetone) contained 0.06% (w/v) of 2-(3- methoxyphenyl)-4-(N-tosyl-L-alanyloxy) thiazole or 2-(2-methoxyphenyl)-4- (N-tosyl-L-alanyloxy) thiazole; 0.05% (w/v) 2-methoxy-4-morpholinobenzene diazonium chloride zinc chloride disalts and 1.0% (w/v) n-decanol. The sedimented paper was dried by heating at 50° C for 5 minutes.
Successful leukocyte assays (i.e., the assays were useful for correctly identifying the presence of leukocytes in urine) were carried out using a diagnostic device that contained each one of the thiazole esters listed in this Example. Each assay was conducted by contacting a test strip (manufactured as described above) with a urine sample. When the urine sample contained leukocytes, the test strip showed the appearance of a violet color. The initial tint of violet color appeared within about 10 seconds and gradually darkened until the reaction was complete, which was about 1 minute. The completed reaction showed a degree of color change that was suitable not only for identifying whether leukocytes were present in the urine sample but also for determining semiquantitatively the concentration of the leukocytes present.
The above specification, examples, and data provide a complete description of the manufacture and the use of the many methods, compounds, compositions, and devices of the invention. Since many embodiments of the invention can be made without departing from the spirit and the scope of the invention, the invention resides in the claims hereinafter appended.

Claims

What is claimed is:
1. A compound of the formula:
Figure imgf000029_0001
or a salt or solvated salt thereof, wherein A is an N-blocked amino acid residue or N-blocked peptide chain; and
Ri is unsubstituted or substituted heteroaryl; alkenyl substituted with unsubstituted or substituted aryl; or alkenyl substituted with unsubstituted or substituted heteroaryl.
2. The compound of claim 1, wherein Ri is heteroaryl substituted with alkyl, alkoxy, alkenyl, amino, acyl, halo, nitro, cyano, hydroxy, or -SO H.
3. The compound of claim 1, wherein Ri is unsubstituted or substituted heteroaryl selected from the group consisting of a 5-membered ring and a 6- membered ring.
4. The compound of claim 1, wherein Ri is unsubstituted or substituted heteroaryl selected from the group consisting of a nitrogen-containing ring, an oxygen-containing ring, and a sulfur-containing ring.
5. The compound of claim 1, wherein Ri is alkenyl selected from the group consisting of ethenyl, propenyl, and butenyl, the alkenyl being substituted with unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl.
6. The compound of claim 1 , wherein Ri is alkenyl substituted with aryl that is unsubstituted phenyl or substituted phenyl.
7. The compound of claim 6, wherein the phenyl is substituted with alkyl, alkenyl, alkoxy, amino, acyl, halo, nitro, cyano, hydroxy, or -SO3H.
8. The compound of claim 1, wherein Rj is alkenyl substituted with substituted heteroaryl, wherein the heteroaryl is substituted with alkyl, alkoxy, alkenyl, amino, acyl, halo, nitro, cyano, hydroxy, or -SO3H.
9. The compound of claim 1, wherein Ri is alkenyl substituted with heteroaryl that is selected from the group consisting of a 5-membered ring and a 6-membered ring.
10. The compound of claim 1 , wherein Ri is alkenyl substituted with heteroaryl that is selected from the group consisting of a nitrogen-containing ring, an oxygen- containing ring, and a sulfur-containing ring.
11. The compound of claim 1 , wherein Ri is heteroaryl substituted with alkyl or alkoxy.
12. A compound of the formula:
Figure imgf000030_0001
or a salt or solvated salt thereof, wherein
A is an N-blocked amino acid residue or N-blocked peptide chain; and R2 is unsubstituted or substituted fused hydrocarbyl rings in which at least one ring is aromatic.
13. The compound of claim 12, wherein R2 is selected from the group consisting of naphthyl, tetrahydronaphthyl, and anthryl.
14. The compound of claim 12, wherein the fused hydrocarbyl rings are substituted on at least one ring with alkyl, alkoxy, alkenyl, amino, acyl, halo, nitro, cyano, hydroxy, or -SOsH.
15. The compound of claim 12, wherein the fused hydrocarbyl rings contain at least one ring selected from the group consisting of a 5-membered ring and a 6- membered ring.
16. The compound of claim 12, wherein the fused hydrocarbyl rings are substituted on at least one ring with alkyl or alkoxy.
17. A compound of the formula:
Figure imgf000031_0001
or a salt or solvated salt thereof, wherein
A is an N-blocked amino acid residue or N-blocked peptide chain; and R3 and R» are each independently hydrogen, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxy, amino, unsubstituted or substituted acyl, halo, nitro, cyano, -SO3H, or hydroxy, wherein R3 and Rtare not both hydrogen.
18. The compound of claim 17, wherein at least one of R3 and R4 is selected from the group consisting of methoxy, ethoxy, propoxy, and butoxy.
19. The compound of claim 17, wherein R3 is hydrogen and R\ is methoxy, ethoxy, propoxy, or butoxy.
20. The compound of claim 19, wherein the position of R is meta or ortho relative to thiazolyl.
21. The compound of any of claims 1 -20, wherein A is N-blocked alanine or N-blocked polyalanine.
22. A composition comprising the compound of any of claims 1-21 and a diazonium salt.
23. The composition of claim 22, wherein the diazonium salt is selected from the group consisting of l-diazo-8-naphtol-3,6-disulfonic acid, chloride, zinc chloride double salt; 6-diazo-l-naphtol-3-sulfonic acid, chloride double salt; and 2— methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt.
24. The composition of claim 22, wherein the composition is free of accelerating salt.
25. A diagnostic device for detecting leukocytes in urine comprising an inert carrier having deposited thereon the compound of any of claims 1-21.
26. The device of claim 25, wherein the inert carrier has a diazonium salt deposited thereon.
27. The device of claim 26, wherein the diazonium salt is selected from the group consisting of l-diazo-8-naphtol-3,6-disulfonic acid, chloride, zinc chloride double salt; diazonium salt is 6-diazo-l-naphtol-3-sulfonic acid, chloride double salt; and 2-methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt.
28. The device of claim 25, wherein the inert carrier is filter paper.
29. The device of claim 25, wherein the device is free of accelerating salt.
30. A method of detecting the presence of leukocytes in urine comprising contacting a urine sample with a diazonium salt and the compound of any of claim 1-21.
31. The method of claim 30, wherein the diazonium salt is selected from the group consisting of l-diazo-8-naphtol-3,6-disulfonic acid, chloride, zinc chloride double salt; 6-diazo-l-naphtol-3-sulfonic acid, chloride double salt; and 2- methoxy-4-morpholinobenzene diazonium chloride, zinc chloride double salt.
32. The method of claim 30, wherein the method is free of accelerating salt.
PCT/US2000/001333 1999-01-21 2000-01-20 Composition and device for detecting leukocytes in urine WO2000043535A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00904434A EP1163360A2 (en) 1999-01-21 2000-01-20 Composition and device for detecting leukocytes in urine
AU26195/00A AU2619500A (en) 1999-01-21 2000-01-20 Composition and device for detecting leukocytes in urine
JP2000594943A JP2002535342A (en) 1999-01-21 2000-01-20 Compositions and devices for assaying leukocytes in urine
CA002359689A CA2359689A1 (en) 1999-01-21 2000-01-20 Composition and device for detecting leukocytes in urine

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11661399P 1999-01-21 1999-01-21
US60/116,613 1999-01-21
US14338399P 1999-07-12 1999-07-12
US60/143,383 1999-07-12
US09/365,592 1999-07-30
US09/365,322 US6348324B1 (en) 1999-01-21 1999-07-30 Composition and device for detecting leukocytes in urine
US09/365,322 1999-07-30
US09/365,592 US6528652B1 (en) 1999-01-21 1999-07-30 Composition and device for detecting leukocytes in urine

Publications (2)

Publication Number Publication Date
WO2000043535A2 true WO2000043535A2 (en) 2000-07-27
WO2000043535A3 WO2000043535A3 (en) 2000-11-30

Family

ID=27494092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001333 WO2000043535A2 (en) 1999-01-21 2000-01-20 Composition and device for detecting leukocytes in urine

Country Status (6)

Country Link
EP (1) EP1163360A2 (en)
JP (1) JP2002535342A (en)
AU (1) AU2619500A (en)
CA (1) CA2359689A1 (en)
HU (1) HUP0105041A2 (en)
WO (1) WO2000043535A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750359A (en) * 1996-07-30 1998-05-12 Chung-Do Pharmaceutical Co., Ltd. Composition for detecting leucocyte and proteinase in urine and its measuring device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750359A (en) * 1996-07-30 1998-05-12 Chung-Do Pharmaceutical Co., Ltd. Composition for detecting leucocyte and proteinase in urine and its measuring device

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI, Week 198849, Derwent Publications Ltd., London, GB; Class A61B, AN 1988-352424, XP002901013 & SU 1399661 A (RIGA MEDKINE INST.), 30 May 1988, *
DATABASE WPI, Week 199546, Derwent Publications Ltd., London, GB; Class C07D, AN 1995-355242, XP002901012 & JP 7242639 (WAKO PURE CHEM. IND. LTD.), *

Also Published As

Publication number Publication date
AU2619500A (en) 2000-08-07
HUP0105041A2 (en) 2002-05-29
WO2000043535A3 (en) 2000-11-30
JP2002535342A (en) 2002-10-22
CA2359689A1 (en) 2000-07-27
EP1163360A2 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
FI85990C (en) SAMMANSAETTNING INNEHAOLLANDE ZWITTERJONKOPPLINGSMEDEL OCH TESTANORDNING FOER BESTAEMNING AV LEUKOCYTER.
FI85988B (en) SCREENINGSFOERFARANDE FOER GRAM-NEGATIVA BAKTERIER OCH FOER BAKTERURI ORSAKAD AV DESSA, I SCREENINGSFOERFARANDET ANVAENDBAR ENHETLIG SCREENINGSANORDNING OCH FOERFARANDE FOER FRAMSTAELLNING AV DEN.
NO164866B (en) REAGENT AND INQUIRY DEVICE FOR DETERMINING THE PRESENCE OF LEUKOCYTES, ESTERASE AND PROTEASE IN A TEST.
JP2732501B2 (en) Substrates for β-galactosidase
US5750359A (en) Composition for detecting leucocyte and proteinase in urine and its measuring device
US6503725B2 (en) Composition and device for detecting leukocytes in urine
US6528652B1 (en) Composition and device for detecting leukocytes in urine
Kimura et al. New reagents for the introduction of the thiomethyl group at sulfhydryl residues of proteins with concomitant spectrophotometric titration of the sulfhydryls: methyl 3-nitro-2-pyridyl disulfide and methyl 2-pyridyl disulfide
US4257940A (en) Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same
US4308202A (en) Prolylphenylalanylarginine derivatives, process for producing same and method for measuring activity of enzymes using same
EP1163360A2 (en) Composition and device for detecting leukocytes in urine
GB2085447A (en) Phenylalanylarginine derivatives process for their preparation and their use for measuring enzyme activity
JP5016752B2 (en) Trypsin substrate, diagnostic tool and method of use thereof
CN115557853A (en) Leucine aminopeptidase fluorescent probe and preparation method and application thereof
GB2034325A (en) Phenyl-alanylvalylargini derivatives process for their preparation and their use for measuring enzyme activity
WO1998025952A1 (en) Peptides, methods for assaying human pepsinogen i or human pepsin i, and assay kits
GB2034718A (en) Prolylphenylalanylarginine Derivatives, Process for Their Preparation and Their Use for Measuring Enzyme Activity
JP3734109B2 (en) Novel enzyme activity measurement substrate and proteolytic enzyme measurement method using the same
KR100816200B1 (en) Novel 8-hydroxyquinoline acetamide compound and preparation method thereof
US4418012A (en) Leucylalany-arginine derivative
JPS6112898B2 (en)
JPS6342638B2 (en)
DD297965A5 (en) CHROMOGENIC DIBENZOXAZEPINONE AND DIBENZOTHIAZEPINONE ENZYME SUBSTRATES
JPS596898A (en) Method for measuring activity of aminopeptidase and synthetic substrate used therefor
JP2660864B2 (en) Aminoacetophenone derivatives and methods for measuring enzyme activity using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00612/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 594943

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2359689

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000904434

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000904434

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2359689

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000904434

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)